Cargando…
Integration of a Miniature Quartz Crystal Microbalance with a Microfluidic Chip for Amyloid Beta-Aβ(42) Quantitation
A miniature quartz crystal microbalance (mQCM) was integrated with a polydimethylsiloxane (PDMS) microfluidic device for on-chip determination of amyloid polypeptide–Aβ(42). The integration techniques included photolithography and plasma coupling. Aβ(42) antibody was immobilized on the mQCM surface...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4634447/ https://www.ncbi.nlm.nih.gov/pubmed/26473864 http://dx.doi.org/10.3390/s151025746 |
Sumario: | A miniature quartz crystal microbalance (mQCM) was integrated with a polydimethylsiloxane (PDMS) microfluidic device for on-chip determination of amyloid polypeptide–Aβ(42). The integration techniques included photolithography and plasma coupling. Aβ(42) antibody was immobilized on the mQCM surface using a cross-linker method, and the resonance frequency of mQCM shifted negatively due to antibody-antigen binding. A linear range from 0.1 µM to 3.2 µM was achieved. By using matrix elimination buffer, i.e., matrix phosphate buffer containing 500 µg/mL dextran and 0.5% Tween 20, Aβ(42) could be successfully detected in the presence of 75% human serum. Additionally, high temperature treatments at 150 °C provided a valid method to recover mQCM, and PDMS-mQCM microfluidic device could be reused to some extent. Since the detectable Aβ(42) concentration could be as low as 0.1 µM, which is close to cut-off value for Alzheimer patients, the PDMS-mQCM device could be applied in early Alzheimer’s disease diagnosis. |
---|